ArticleBiosensors & bioelectronics2025
Comparative visible-light and near-infrared fluorescence detection of microRNA in blood plasma with paper lateral flow test strips.
Article in Biosensors & bioelectronics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multifaceted roles of miR‑124 in cancer: Molecular mechanisms and clinical prospects (Review).International journal of oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Prevailing colorimetric paper lateral flow strips (PLFSs) are inexpensive and easy to use by untrained personnel, but suffer from low sensitivity and severe interference from complex sample matrices such as blood plasma. Hence, a PLFS based on near-infrared fluorescence (NIRF) has been developed to directly detect microRNA (miRNA) in blood plasma without any further sample pretreatment. To mitigate the issue of low intensity and photo-instability of organic NIRF dye molecules, the dye-encapsulated silica nanoparticles have been synthesized and incorporated into a PLFS for miRNA detection. To demonstrate the advantage of NIRF, a PLFS based on visible-light fluorescence (VisF) has also been constructed as the control. The test results reveal that the NIRF-PLFS with fluorescence emission at 773 nm exhibits sensing performance comparable to the VisF-PLFS with fluorescence emission at 542 nm when measuring miRNA in buffer solution. However, the NIRF-PLFS shows far superior performance over the VisF-PLFS in terms of the linear detection range and the limit of detection when measuring miRNA in blood plasma samples. The NIRF-PLFS has achieved a limit of detection of 50 pM toward miRNA in the diluted blood plasma sample, two orders of magnitude lower than that of the VisF-PLFS. The developed NIRF-PLFS exhibits great potential as a point-of-care (POC) tool in detection of disease biomarkers in human fluid samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.